Platelet glycoprotein receptor Ib blockade ameliorates experimental cerebral ischemia –reperfusion injury by strengthening the blood–brain barrier function and anti-thrombo-inflammatory property

Publication date: Available online 28 November 2017 Source:Brain, Behavior, and Immunity Author(s): Chunyan Chen, Tingting Li, Yuchen Zhao, Yinfeng Qian, Xiaoyi Li, Xiangrong Dai, Dake Huang, Tianzhong Pan, Lanlan Zhou Blood-brain barrier (BBB) disruption, thrombus formation and immune-mediated inflammation are important steps in the pathophysiology of cerebral ischemia–reperfusion injury but are still inaccessible to therapeutic interventions. Recent studies have provided increasing evidence that blocking of platelet glycoprotein (GP) receptor Ib might represent a novel target in treating acute ischemic stroke. This research was conducted to explore the therapeutic efficacy and potential mechanisms of GPIbα inhibitor (anfibatide) in a model of brain ischemia–reperfusion injury in mice. Male mice underwent 90 min of right middle cerebral artery occlusion (MCAO) followed by 24 h of reperfusion. Anfibatide (1, 2, 4 ug/kg) or tirofiban were administered intravenously 1 h after reperfusion. The results showed that anfibatide could significantly reduce infarct volumes, increase the number of intact neuronal cells and improve neurobehavioral function. Moreover, anfibatide could reduce post ischemic BBB damage by attenuating increased paracellular permeability in the ischemia hemisphere significantly. Stroke-induced increases in activity and protein expression of macrophage-1 antigen (MAC-1) and P-selectin were also reduced by anfibatide intervention. Finally...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research